Live from the NIH registry
Studies recruiting near Scranton right now
Top 25 of 100 recruiting studies, sorted by proximity — each links to its official registry page
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma
Phase 2
Interventional 188 participants sought
Geisinger Wyoming Valley/Henry Cancer Center — Wilkes-Barre, Pennsylvania (15.7 mi)
· Sponsor: National Cancer Institute (NCI)
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
Cataract
Phase 3
Interventional 528 participants sought
Northeastern Eye Institute — Scranton, Pennsylvania (0.3 mi)
· Sponsor: Melt Pharmaceuticals
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia
Phase 2
Interventional 93 participants sought
Geisinger Wyoming Valley/Henry Cancer Center — Wilkes-Barre, Pennsylvania (15.7 mi)
· Sponsor: National Cancer Institute (NCI)
Stroke Thrombectomy and Aneurysm Registry
Stroke, Thromboses, Intracranial
N/A
Observational 40,000 participants sought
Geisinger Medical Group — Wilkes-Barre, Pennsylvania (15.7 mi)
· Sponsor: Medical University of South Carolina
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma
Phase 3
Interventional 1,450 participants sought
Community Medical Center — Scranton, Pennsylvania (0.3 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Phase 2
Interventional 2,000 participants sought
Geisinger Wyoming Valley/Henry Cancer Center — Wilkes-Barre, Pennsylvania (15.7 mi)
· Sponsor: National Cancer Institute (NCI)
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
Brain Metastases
Phase 3
Interventional 206 participants sought
Geisinger Wyoming Valley/Henry Cancer Center — Wilkes-Barre, Pennsylvania (15.7 mi)
· Sponsor: Canadian Cancer Trials Group
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Breast Carcinoma, Colorectal Carcinoma
N/A
Observational 2,000 participants sought
Community Medical Center — Scranton, Pennsylvania (0.3 mi)
· Sponsor: Wake Forest University Health Sciences
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Prostate Cancer (Adenocarcinoma)
Phase 3
Interventional 830 participants sought
Community Medical Center — Scranton, Pennsylvania (0.3 mi)
· Sponsor: Canadian Cancer Trials Group
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Stage I Breast Cancer
Phase 3
Interventional 1,670 participants sought
Northeast Radiation Oncology Center — Dunmore, Pennsylvania (2.0 mi)
· Sponsor: NRG Oncology
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
Breast Cancer, Cognitive Impairments
N/A
Interventional 386 participants sought
Community Medical Center — Scranton, Pennsylvania (0.3 mi)
· Sponsor: NRG Oncology
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Intracranial Meningioma, Recurrent Meningioma
Phase 2
Interventional 124 participants sought
Community Medical Center — Scranton, Pennsylvania (0.3 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Extensive Stage Lung Small Cell Carcinoma
Phase 2, Phase 3
Interventional 138 participants sought
Geisinger Cancer Center Dickson City — Dickson City, Pennsylvania (5.5 mi)
· Sponsor: National Cancer Institute (NCI)
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain
Phase 3
Interventional 200 participants sought
Geisinger Wyoming Valley/Henry Cancer Center — Wilkes-Barre, Pennsylvania (15.7 mi)
· Sponsor: NRG Oncology
Clarifying the Optimal Application of SLT Therapy Trial
Glaucoma and Ocular Hypertension
Phase 3
Interventional 790 participants sought
Eye Care Specialists — Kingston, Pennsylvania (15.6 mi)
· Sponsor: University of Pittsburgh
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Phase 3
Interventional 3,680 participants sought
Community Medical Center — Scranton, Pennsylvania (0.3 mi)
· Sponsor: National Cancer Institute (NCI)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma
Phase 3
Interventional 1,210 participants sought
Community Medical Center — Scranton, Pennsylvania (0.3 mi)
· Sponsor: National Cancer Institute (NCI)
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Phase 3
Interventional 1,524 participants sought
Geisinger Cancer Center Dickson City — Dickson City, Pennsylvania (5.5 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 10,000 participants sought
Community Medical Center — Scranton, Pennsylvania (0.3 mi)
· Sponsor: SWOG Cancer Research Network
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Multiple conditions
N/A
Observational 2,000 participants sought
Geisinger Wyoming Valley/Henry Cancer Center — Wilkes-Barre, Pennsylvania (15.7 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
An Internet-based Program to Help Cancer Survivors Manage Pain
Cancer
N/A
Interventional 456 participants sought
Community Medical Center — Scranton, Pennsylvania (0.3 mi)
· Sponsor: Wake Forest University Health Sciences
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Major Depressive Disorder
Phase 2
Interventional 164 participants sought
Scranton Medical Institute, LLC — Moosic, Pennsylvania (5.2 mi)
· Sponsor: Syndeio Biosciences, Inc
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
Phase 2
Interventional 240 participants sought
Community Medical Center — Scranton, Pennsylvania (0.3 mi)
· Sponsor: NRG Oncology
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
Obstructive Hypertrophic Cardiomyopathy
N/A
Observational 1,700 participants sought
Geisinger Health System — Wilkes-Barre, Pennsylvania (15.7 mi)
· Sponsor: Bristol-Myers Squibb
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma
Phase 3
Interventional 320 participants sought
Geisinger Cancer Center Dickson City — Dickson City, Pennsylvania (5.5 mi)
· Sponsor: National Cancer Institute (NCI)